Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study

Serum 25-Hydroxyvitamin D Concentrations and Risk for Hip Fractures

(2013) Jane A. Cauley   ANNALS OF INTERNAL MEDICINE

Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer

(2011) Sònia Servitja et al.   BREAST

Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial

(2011) Antonella L. Rastelli et al.   BREAST CANCER RESEARCH AND TREATMENT

Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men

(2011) Jane A Cauley et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women

(2010) Kerrie M. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know

(2010) A. Catharine Ross et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

(2010) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

(2010) Catherine Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer

(2010) Xavier Nogues et al.   MATURITAS

Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency

(2009) Heike A. Bischoff-Ferrari et al.   ARCHIVES OF INTERNAL MEDICINE

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

(2009) Stephanie L. Hines et al.   BREAST CANCER RESEARCH AND TREATMENT

Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study

(2009) Georgiana K. Ellis et al.   BREAST CANCER RESEARCH AND TREATMENT

A review of the BIG results: the Breast International Group 1–98 trial analyses

(2008) J.C. Doughty   BREAST

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

(2008) Nigel J. Bundred et al.   CANCER

Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group

(2008) David M. Reid et al.   CANCER TREATMENT REVIEWS

Dietary Calcium and Serum 25-Hydroxyvitamin D Status in Relation to BMD Among U.S. Adults

(2008) Heike A Bischoff-Ferrari et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial

(2008) Diana Crivellari et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

(2008) Richard Eastell et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

(2008) Michael Gnant et al.   LANCET ONCOLOGY